JYNNEOS Vaccine Fails to Stop Monkeypox Disease in the United States

Disappointing Results on Protection From Male Sexually Transmitted Disease

By Peter A. McCullough, MD, MPH

President Biden dropped the Monkeypox National Emergency Declaration on January 31, 2023, after it was clear that human to human transmission occurred in largely younger men having sex with other men. Older individuals after age 50 appeared to be protected from childhood smallpox vaccination and those without dangerous sexual behavioral profiles were not at risk. Additionally, Monkeypox (MPOX)

was readily treatable with tecovirimat, a safe and effective medication available orally and intravenously.

Approximately 1.2 million Americans were encouraged to take the Bavarian Nordic Jynneos vaccine without any prior randomized trials demonstrating safety or efficacy in humans. Now the medical community is learning about the failure of the Jynneos vaccine in the peer reviewed literature. Because case-control methodology tends to overestimate vaccine efficacy and is not an adequate replacement for a randomized trial, when we see vaccine efficacy far less than 90%, the real protection is likely to be very disappointing.